Clinical trials: Blood Pressure Reduction
Blood Pressure, HDL Low
Effects of a 10 Component Dietary Supplement on Health and the Quality of Life
This open-label field trial evaluates the effects of treatment with a multi-pathway dietary supplement (Stem Cell 100+) that has been commercially available for several years.
- Conditions
- Blood Pressure, HDL Low, Stress, Lung Function Decreased
- Trial name
- NCT03052491
- Testing
- Stem Cell 100+
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centagen, Inc.
Essential Hypertension
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.
- Trial name
- NCT01848873
- Testing
- Amlodipine, amlodipine-FA tablet, low dose group, amlodipine-FA tablet ,high dose group
- Where
- 16 sites in China
- Volunteers
- 756 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
High Risk Cardiovascular Disease, Hypertension
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events.
- Conditions
- High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
- Trial name
- ZENITH (NCT07181109)
- Testing
- Zilebesiran
- Where
- 1,190 sites in United States, Argentina and 33 more
- Volunteers
- 11,000 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension
Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
This study will be compare Felodipine sustained-release tablets, to Lercanidipine hydrochloride tablets (Zanidip®) for the treatment of patients with mild-to-moderate primary hypertension and to investigate the influence on…
- Trial name
- Zanidip (NCT01520285)
- Testing
- Zanidip, Felodipine sustained-release tablet
- Where
- China
- Volunteers
- 281 people
- Sponsor
- Lee's Pharmaceutical Limited
Cardiovascular Diseases
Evaluating the Effectiveness of a Computerized Medication Adherence System at Reducing Cardiovascular Disease Risk Factors
High blood pressure and high cholesterol are both causes of cardiovascular disease (CVD), and it is important for people with these conditions to adhere to their medication regimens.
- Trial name
- NCT00796172
- Testing
- Medication Adherence System (MAS), Usual Care
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- PHCC LP
Hypertension, Dyslipidemias
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive…
- Trial name
- NCT05660135
- Testing
- Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
- Where
- South Korea
- Volunteers
- 4,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension
Blood Pressure Reduction in Danish General Practice (BRIDGE)
To investigate the effect on blood pressure (BP) control in hypertensive patients using a combination of frequent home - and 24-h ambulatory blood pressure measurement (ABPM) in a Danish general practice (GP) setting.
- Trial name
- NCT00244660
- Testing
- Frequent blood pressure measurements, Education
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Boehringer Ingelheim
Obesity, Hypertension
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
The purpose of this study is to determine the efficacy of candesartan, once daily (QD), combined with hydrochlorothiazide to lower blood pressure in insulin-resistant, obese patients with hypertension.
- Trial name
- NCT00775814
- Testing
- Candesartan and Hydrochlorothiazide, Hydrochlorothiazide (HCT)
- Where
- 24 sites in Germany
- Volunteers
- 188 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Hypertension
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of…
- Trial name
- NCT01939496
- Testing
- Canagliflozin
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- Janssen Scientific Affairs, LLC
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Hypertension
Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
The purpose of this study is to evaluate the effect of home blood pressure monitoring on controlling blood pressure and correlation between home blood pressure and clinic blood pressure in hypertensive patients receiving two or…
- Trial name
- NCT03254914
- Testing
- Home Blood Pressure
- Where
- South Korea
- Volunteers
- 3,554 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.
- Trial name
- VIPER-BP (NCT00902304)
- Testing
- Valsartan and hydrochlorothiazide (HCTZ) - monotherapy, Valsartan and amlodipine, Usual care
- Where
- 3 sites in United States, Australia
- Volunteers
- 2,337 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Olmesartan in Essential Hypertension
To test the efficacy and safety of olmesartan in patients with essential hypertension.
- Trial name
- NCT00185172
- Testing
- olmesartan medoxomil, olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets
- Where
- 8 sites in Austria, Germany and 6 more
- Volunteers
- 2,333 people
- Sponsor
- Sankyo Pharma Gmbh
Hypertension
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in…
- Trial name
- NCT00434967
- Testing
- Candesartan cilexetil, Hydrochlorothiazide, Candesartan/HCT 32/25 mg
- Where
- 27 sites in Belgium, Latvia and 4 more
- Volunteers
- 2,207 people
- Sponsor
- AstraZeneca
Hypertension
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)
The study compares the efficacy of an aggressive versus a moderate initial antihypertensive regimen to reduce blood pressure in patients with Stage 2 hypertension.
- Trial name
- NCT00154271
- Testing
- Valsartan, Valsartan HCT
- Volunteers
- 1,677 people
- Sponsor
- Novartis
Essential Hypertension
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-Folic Acid Tablets on reduction of blood pressure and plasma total homocysteine.
- Trial name
- NCT01956786
- Testing
- Amlodipine-FA tablet,low dose group, Amlodipine-FA tablet,high dose group, Amlodipine
- Where
- 3 sites in China
- Volunteers
- 540 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Decreased and Nonspecific Blood Pressure Disorders and Shock
Comparison of HES 130 in Balanced and in Unbalanced Solution
The purpose of this study is to evaluate the efficacy of HES 130/0.42 in an electrolyte infusion in comparison to HES 130/0.4 in a sodium chloride infusion.
- Trial name
- NCT01301469
- Testing
- 6% HES 130/0.42 in plasma adapted Ringer's solution, 6% HES 130/0.4 in a saline solution
- Where
- 4 sites in China
- Volunteers
- 240 people
- Sponsor
- B. Braun Melsungen AG
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg compared to a more conventional approach…
- Trial name
- NCT00280540
- Testing
- Valsartan/Hydrochlorothiazide
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- Novartis
Type 2 Diabetes, Hypertension
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.
- Trial name
- NCT00654745
- Testing
- Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide
- Where
- 21 sites in United States
- Volunteers
- 207 people
- Sponsor
- Daiichi Sankyo